down arrow

Ventyx Biosciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US92332V1070
USD
8.74
1 (12.92%)

Dec 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

7.788.92

52 Week

0.7810.55
Valuation
Technical
Day's Volume

CASH

2.84 M

Shareholding (Jun 2025)

FII

16.82%

Held by 86 FIIs

DII

42.47%

Held by 43 DIIs

Promoter

6.68%

How big is Ventyx Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Ventyx Biosciences, Inc. has a market capitalization of 156.55 million, with net sales of 0.00 million and a net profit of -123.99 million over the latest four quarters. The company reported shareholder's funds of 254.04 million and total assets of 278.67 million as of Dec 24.

Market Cap: As of Jun 18, Ventyx Biosciences, Inc. has a market capitalization of 156.55 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Ventyx Biosciences, Inc. reported net sales of 0.00 million and a net profit of -123.99 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 254.04 million and total assets of 278.67 million.

Read More

What does Ventyx Biosciences, Inc. do?

22-Jun-2025

Ventyx Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $27 million and a market cap of $156.55 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -53.40%.

Overview: <BR>Ventyx Biosciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -27 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 156.55 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.98 <BR>Return on Equity: -53.40% <BR>Price to Book: 0.68<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Ventyx Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Ventyx Biosciences, Inc. is in a mildly bearish trend, with weekly indicators suggesting weakness despite some bullish signals on the monthly chart, and the stock has underperformed the S&P 500 with a -15.55% return over the past month compared to the S&P's 2.33%.

As of 12 September 2025, the technical trend for Ventyx Biosciences, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST indicators, both of which are mildly bearish. The monthly MACD shows a mildly bullish signal, but this is countered by the bearish monthly Bollinger Bands and KST. The daily moving averages indicate a mildly bullish trend, but overall, the weekly indicators dominate the analysis.<BR><BR>In terms of performance, the stock has underperformed compared to the S&P 500 over the past month, with a return of -15.55% versus the S&P's 2.33%. Over the year, Ventyx has returned 4.37%, significantly lagging behind the S&P's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 170 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.99

stock-summary
Return on Equity

-56.70%

stock-summary
Price to Book

0.81

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-27 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
280.0%
0%
280.0%
6 Months
268.78%
0%
268.78%
1 Year
283.33%
0%
283.33%
2 Years
308.41%
0%
308.41%
3 Years
-72.55%
0%
-72.55%
4 Years
-39.64%
0%
-39.64%
5 Years
0%
0%
0.0%

Ventyx Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-364.28%
EBIT to Interest (avg)
-105.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.98
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.76
EV to EBIT
0.39
EV to EBITDA
0.39
EV to Capital Employed
-13.43
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-53.40%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 49 Schemes (34.03%)

Foreign Institutions

Held by 86 Foreign Institutions (16.82%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 15.36% vs 40.15% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-29.00",
          "val2": "-35.40",
          "chgp": "18.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-27.00",
          "val2": "-31.90",
          "chgp": "15.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 30.00% vs -78.04% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-146.80",
          "val2": "-204.60",
          "chgp": "28.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.30",
          "val2": "-2.50",
          "chgp": "88.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-135.10",
          "val2": "-193.00",
          "chgp": "30.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-29.00
-35.40
18.08%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-27.00
-31.90
15.36%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 15.36% vs 40.15% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-146.80
-204.60
28.25%
Interest
0.00
0.00
Exceptional Items
-0.30
-2.50
88.00%
Consolidate Net Profit
-135.10
-193.00
30.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 30.00% vs -78.04% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Ventyx Biosciences, Inc. stock-summary
stock-summary
Ventyx Biosciences, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."